Format

Send to

Choose Destination
J Lipid Res. 2014 Jun;55(6):1139-49. doi: 10.1194/jlr.P042176. Epub 2013 Dec 16.

Bioactive lipid mediators in polycystic kidney disease.

Author information

1
Department of AnesthesiologyUniversity of Colorado, Aurora, CO Division of Renal Diseases and Hypertension, University of Colorado, Aurora, CO.
2
Department of AnesthesiologyUniversity of Colorado, Aurora, CO.
3
Division of Renal Diseases and Hypertension, University of Colorado, Aurora, CO.
4
Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA.

Abstract

Inflammatory activity is evident in patients with chronic kidney disease with limited data available in autosomal dominant polycystic kidney disease (ADPKD). We hypothesized that inflammation is an upstream event in the pathogenesis of ADPKD and may be a contributing factor in the disease severity and progression. Serum samples from 61 HALT study A group patients were compared with samples from 49 patients from HALT study B group with moderately advanced disease. Targeted MS analysis of bioactive lipid mediators as markers of inflammation was performed and correlated with eGFR and total kidney volume (TKV) normalized to the body surface area (BSAR) to assess if these markers are predictive of ADPKD severity. ADPKD patients with eGFR >60 ml/min/1.73 m(2) showed higher levels of 5- and 12/15-lipoxygenase (LOX) and cyclooxygenase, and generated higher levels of hydroxy-octadecadienoic acids 9-HODE and 13-HODE and HETEs 8-HETE, 11-HETE, 12-HETE, and 15-HETE as compared with healthy subjects. Linear regression of 9-HODE and 13-HODE revealed a significant relationship with eGFR and TKV, while 15-HETE significantly correlated with TKV/BSAR. Production of 20-HETE, a P450-produced metabolite of arachidonic acid, was higher in ADPKD patients as compared with healthy subjects and significantly correlated with eGFR and TKV/BSAR. Perturbation in fatty acid metabolism is evident early in ADPKD patients, even in those with preserved kidney function. The identified LOX pathways may be potential therapeutic targets for slowing down ADPKD progression.

KEYWORDS:

arachidonic acid; autosomal dominant polycystic kidney disease; bioactive lipid biomarkers; liquid chromatography-mass spectrometry

PMID:
24343898
PMCID:
PMC4031945
DOI:
10.1194/jlr.P042176
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center